Neomycin and Polymyxin B Sulfates
Brand Names: Neomycin and Polymyxin B Sulfates Generic
Methodology & AI Transparency ⓘ
Neomycin and Polymyxin B Sulfates Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Neomycin and Polymyxin B Sulfates (40 mg/mL / 200000 [USP'U]/mL Solution; NDC 39822-1220, 39822-1201) as a irrigation-route aminoglycoside antibacterial formulation manufactured/labeled by XGen Pharmaceuticals DJB, Inc.
- 2 Real-world patient consensus: 81% patient "Worth It" rating across 5 anonymous logs for Neomycin and Polymyxin B Sulfates (RxNorm RXN-398221220-3156).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $46.55 cash mean against $114.05 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Neomycin and Polymyxin B Sulfates: diarrhea (8.3%), nausea (8.3%), headache (5.4%).
Ask our AI Specialists anything about Neomycin and Polymyxin B Sulfates
Neomycin and Polymyxin B Sulfates Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Neomycin and Polymyxin B Sulfates (40 mg/mL / 200000 [USP'U]/mL Solution; NDC 39822-1220, 39822-1201) as a irrigation-route aminoglycoside antibacterial formulation manufactured/labeled by XGen Pharmaceuticals DJB, Inc. when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Neomycin and Polymyxin B Sulfates exerts selective aminoglycoside antibacterial pharmacodynamic activity across 40 mg/mL / 200000 [USP'U]/mL Solution (irrigation-route route, manufactured/labeled by XGen Pharmaceuticals DJB, Inc.), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 39822-1220, 39822-1201).
With Terminal t½ estimated at 4–11 hrs depending on renal/hepatic reserve (Neomycin and Polymyxin B Sulfates) residence kinetics and F ≈ 45%–57% systemic availability after standard oral Neomycin and Polymyxin B Sulfates administration bioavailability, Neomycin and Polymyxin B Sulfates undergoes mixed metabolic conjugation and unchanged urinary excretion across neomycin and polymyxin b sulfates regimens and establishes therapeutic activity over time to peak concentration spans 1 to 2 hrs under neomycin and polymyxin b sulfates maintenance.
Standard adult regimens span 40 mg/mL / 200000 [USP'U]/mL Solution, 40 mg/mL. Prescribers screen specifically against known hypersensitivity to neomycin and polymyxin b sulfates or structurally related aminoglycoside antibacterial compounds; concomitant contra-labeled cyp/transporter therapies during active neomycin and polymyxin b sulfates administration, while community micro-logs most frequently note nausea (8.3% of reports), diarrhea (8.3% of reports), headache (5.4% of reports).
Avoid overlapping aminoglycoside antibacterial prescriptions alongside Neomycin and Polymyxin B Sulfates to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Neomycin and Polymyxin B Sulfates maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Neomycin and Polymyxin B Sulfates or structurally related aminoglycoside antibacterial compounds
- Concomitant contra-labeled CYP/transporter therapies during active Neomycin and Polymyxin B Sulfates administration
Logged Side-Effect Incidence (5 Reports)
Neomycin and Polymyxin B Sulfates Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Neomycin and Polymyxin B Sulfates)
Human clinical trial evidence for Neomycin and Polymyxin B Sulfates is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Neomycin and Polymyxin B Sulfates Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9395/unit (~$28.18/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $114.05 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $46.55 / mo | View logs ↓ |
Neomycin and Polymyxin B Sulfates Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Neomycin and Polymyxin B Sulfates RxNorm Concept ID | RXN-398221220-3156 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9395 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $114.05 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $46.55 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Neomycin and Polymyxin B Sulfates Patient Community, Cohort Filters & Dosage Logs
Cross-verified Neomycin and Polymyxin B Sulfates (aminoglycoside antibacterial) monograph synthesizing RxNorm RXN-398221220-3156, openFDA FAERS signals, and $46.55–$114.05 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Neomycin and Polymyxin B Sulfates community threads and patient logs by age, biological sex, dosage, and treatment duration.